EGFR and neoplasm: The authors found that a combination of PAFR antagonist (WEB2086) and EGFR inhibitor (AG1478) resulted in significantly increased inhibition of proliferation and invasion of CAOV3 and SKOV3 cell lines, as well as decreased growth of CAOV3 tumor xenografts in athymic nude mice compared to these drugs alone [36].